Science AdvancesBiochemistryPeer-reviewed journal article
Mechanism and cellular actions of the potent AMPK inhibitor BAY-3827
Conchita Fraguas BringasiD, Mohd Syed AhangariD, Joyceline CuencoiD, Hongling LiuiD, Alex Bernard AddinsalliD, Maria Lindahl, Ashley J. OvensiD, Mark Anthony FebbraioiD, Marc ForetziD, Olga GöranssoniD, John W. ScottiD, Elton ZeqirajiD, Kei SakamotoiD
Abstract
Inhibition of AMP-activated protein kinase (AMPK) is under increasing investigation for its therapeutic potential in many diseases, including certain cancers. However, existing AMPK- inhibitors available as tool compounds are largely limited to compound C/dorsomorphin and SBI-0206965, both of which suffer from poor selectivity and off-target effects. Here we describe the structure-based molecular insights and cellular actions of a recently identified potent AMPK inhibitor, BAY-3827. Kinase selectivity profiling and sequence analyses of kinases that are highly or weakly inhibited by BAY-3827 uncovered key conserved residues involved in its inhibitory mechanism. A 2.5 [A] co-crystal structure of the AMPK kinase domain (KD)-BAY-3827 complex and comparison with known KD-inhibitor structures, revealed an overlapping site in the ATP-binding pocket and an C helix-out conformation. A distinct feature of the BAY-3827-bound state is the formation of a disulfide bridge between the D helix Cys106 and the activation loop residue Cys174. This bridge appears to stabilize the activation loop such that Asn162 repositions the DFG motif Phe158 toward the C-terminal kinase lobe, displacing His137 and disrupting the regulatory spine, thereby promoting an inactive state. In hepatocytes, 2.5-5 M BAY-3827, but not the structurally resembling inactive BAY-974, fully blocked AMPK activator (MK-8722)-mediated phosphorylation of ACC1 and corresponding inhibition of lipogenesis. Unbiased transcriptome analysis in MK- 8722-treated wild-type and AMPK-null hepatocytes revealed that 5 M BAY-3827 downregulated >30% of MK-8722-stimulated AMPK-dependent genes. Based on its greater selectivity and potency substantiated by comprehensive structural and cellular investigations, BAY-3827 is a powerful tool to delineate AMPK functions. One-sentence summaryWe provide the mechanism of action of the potent and selective AMPK inhibitor BAY-3827, which blocks AMPK-dependent cellular functions.
- Citations
- 12
- FWCI
- 3.59
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Crystal structure of activated MAPKAPK2 kinase reveals a C-lobe allosteric pocket for furan-2-carboxamide inhibitors
Edward Beaumont, Stéphanie Duclos, … john Barker·bioRxiv·Oct 7, 2026
- Novel torin1-sensitive phosphorylation sites on the metabolic regulator AMPK revealed by label-free mass spectrometry
W. J. Smiles, A. J. Ovens, … J. S. Oakhill·bioRxiv·Oct 20, 2021
- In-silico identification of Tyr232 in AMPKα2 as a dephosphorylation site for the protein tyrosine phosphatase PTP-PEST
A. Manikandan, S. TS, … M. Dixit·bioRxiv·May 9, 2022
- Fine tuning energy metabolism in skeletal muscle: Discovery of a novel autoinhibitory mechanism in the N-terminal extension of AMPKγ3
Ashley J. Ovens, Muhammad N.H. Khabib, … Christopher G. Langendorf·bioRxiv·Aug 19, 2026
- Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation
Emily Jane Stadnicki, Hannes Ludewig, … Niels Bradshaw·Proceedings of the National Academy of SciencesPeer-reviewed·Dec 31, 2024
- AMPK Phosphorylation Proceeds Through Hierarchical Proteoform Cascades Revealed by Integrated Mass Spectrometry
Boris Krichel, Hsin‐Ju Chan, … Ying Ge·Science AdvancesPeer-reviewed·Sep 4, 2026